Guest Author: Sokol Todi, PhD; Wayne State University I have been attending the Ataxia Investigators Meeting for nearly a decade. I was a junior faculty at the time of my first participation. I had worked in the Ataxia field for a few years and was looking for a scientific family Read More…
At NAF, we support researchers in many ways, including our grant process. Research grants allow Ataxia investigators to request funding for their studies. Lay summaries are available below for the research grants we funded in 2021. $655,000 Funded Overall 13 Research Studies Funded Research Seed Money Grants Research Seed Money Read More…
NAF, along with Ataxia Global Initiative, and Ataxia UK, recently partnered with Critical Path Institute (C-Path) for the launch of their Critical Path to Therapeutics for the Ataxias (CPTA) Consortium. CPTA is a public-private partnership focused on accelerating the development of treatments for inherited Ataxias. The work of the Consortium will Read More…
Below are lay summaries submitted for research completed in fiscal year 2019. Each study received a grant from NAF to support their research. To check out more information, click the “+” symbol next to the title of the study. Click the “-” symbol to collapse the lay summary for that Read More…
The National Ataxia Foundation (NAF), the Friedreich’s Ataxia Research Alliance (FARA), and Ataxia UK are pleased to announce the date for the inaugural International Congress for Ataxia Research (ICAR) to be held at the Caribe Royale resort in Orlando, Florida, USA on March 15th – 18th, 2022. The Congress will Read More…
Pre-competitive pharma industry consortium looks to accelerate development of treatments for Ataxia The National Ataxia Foundation (NAF) announced today the launch of the NAF Drug Development Collaborative. This pre-competitive pharmaceutical industry consortium has a principal goal of accelerating the development of treatments for Ataxia. The group will address the many Read More…
Author: Mary Ann Peterson, NAF Research Associate Many feel powerless when they are first diagnosed with Ataxia. Brain donation gives the donor and family the power to provide researchers knowledge to fight back against the disease. The examination of diseased brain tissue by a trained researcher remains the gold standard Read More…
Guest Author: Amber Trzeciak, Cadent Therapeutics Clinical trial phases can be a confusing concept to understand. The purpose of clinical trials is to determine how a drug or device (intervention) will interact with a human being. Trials are regulated by our governmental agency the FDA (US Food and Drug Administration). Read More…
The Voice of the Patient Report (PDF) for Polyglutamine Ataxias and DRPLA is now available. This report summarizes information from the Externally-Led Patient Focused Drug Development (EL-PFDD) meeting we hosted on September 25, 2020. We would like to offer our thanks to the patient panelists, phone callers, and individuals who submitted Read More…
Guest Author: Tasha Kaiser, Clinical Research Coordinator, University of Michigan Hello, with a big friendly wave of the Michigan mitten! My name is Tasha Kaiser, and I am the Clinical Research Coordinator for the University of Michigan Ataxia studies. I know that so many of you in the Ataxia community Read More…
Our generous donors help us fund promising Ataxia research and offer support services to people with Ataxia. Your gift today will help us continue to deliver on our mission to improve the lives of persons affected by Ataxia.
Join for FREE today! Become a part of the community that is working together to find a cure. As a member you will receive access to the latest Ataxia news with our e-newsletter and Generations publication.
Mailing Address:
PO Box 27986
Golden Valley, MN 55427
Physical Address:
600 Highway 169 South
Suite 1725
Minneapolis, MN 55426
763-553-0020
763-553-0167 (Fax)
